

24 **Abstract**

25
26 **Introduction:** A serosurvey among health care providers (HCPs) and frontliners of an
27 area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the
28 Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens.

29 **Methods:** Serum samples were collected in a cohort of HCPs and frontliners (n=698)
30 participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens
31 seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group
32 (FANG) ELISA or a Luminex multiplex assay.

33 **Results:** The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10
34 (1.4%: 95% CI, 0.7- 2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95%
35 CI, 0.0 - 1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay.
36 Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9)
37 samples using FANG ELISA.

38 **Conclusion:** In contrast to previous serosurveys, a low seroprevalence was found in the
39 HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende,
40 DRC. This underscores the high need for standardized antibody assays and cutoffs in
41 EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in
42 EBOV endemic areas.

43 **Key words:** EBOV, DRC, EBL2007 trial, GP-EBOV, Luminex, FANG ELISA, Boende,
44 Health care providers, Frontliners.

45

46 **Abstract words count:**195

47

48 **Introduction**

49
50 Ebola virus disease (EVD) was first observed during two simultaneous epidemics in 1976
51 in South Sudan and the Democratic Republic of the Congo (DRC) [1, 2]. Since then, there
52 were fifteen epidemics throughout the DRC, including one in the Boende area, province
53 of Tshuapa in 2014 [3, 4]. The frequency of EVD epidemics in the DRC increased
54 tremendously over the past five years with seven epidemics occurring between 2017 and
55 2022. Mathematical models predict at least one epidemic each year [5]. The increasing
56 trend can partly be explained by an improved surveillance system and better diagnostic
57 tools. Further, villagers are more likely to come into contact with the natural reservoir of
58 Ebolavirus Zaire (EBOV), as pristine habitats in the Congo Basin are transformed into
59 farmland and cut at an unprecedented rate to provide wood for industries [6]. Human
60 encroachment into these new habitats results in increased bushmeat hunting and a higher
61 level of exposure to the virus, which is most likely spilled over from bats or monkeys [7].
62 Furthermore, flare-ups of EVD epidemics might also result from chronically infected
63 patients, which was noted recently in Guinea where a survivor passed the virus on to his
64 partner via semen more than 500 days after contracting EVD [5, 8, 9].

65 While spillover from animals to humans is considered to be rare [10], epidemics are
66 primarily the result of direct person-to-person transmission via body fluids or indirect
67 transmission via contaminated materials [11]. Due to occupational exposure, healthcare
68 providers (HCPs) are more at risk during an outbreak than others in the general
69 community and become a potential source of transmission themselves [12]. For example,
70 during the seventh EVD outbreak in the DRC, which occurred in Boende Health District
71 (2014), three HCPs were identified as potential super-spreaders of community-level
72 disease transmission [13]. Similarly, health facilities may facilitate transmission to the

73 community as infected patients, visitors, and the general public come together there [14,
74 15]. For example, the EBOV epidemic in 1995 was mainly driven by nosocomial
75 transmission at Kikwit General Hospital of DRC [16].

76 While epidemics are typically monitored through PCR-confirmed active cases,
77 serosurveillance data represents the accumulative number of infections and may detect
78 several undiagnosed cases. Indeed, EBOV infections may remain asymptomatic or
79 paucisymptomatic after exposure to the pathogen [17]. This has been observed in recent
80 studies where EBOV antigen seroreactivity is increasingly reported [8, 18, 19]. In
81 unaffected areas, seroreactivity to EBOV-GP was reported in urban areas of Cameroon
82 (1.3%), and DRC in Kinshasa (2%) and Kasai Oriental (3.5%) [8, 18, 20, 21]. In a resident
83 pygmy population including traditional hunters in Watsa locality (Haut-Uele province,
84 DRC) a seroprevalence of 18.7% was reported [8]. A study including HCP and frontliners,
85 regardless of their self-reported history of EVD, found 3.4% of EBOV antigens
86 seroreactivity in Kabondo - Dianda (southeastern DRC and forest-savannah area) [22]. A
87 serosurvey conducted at the end of the 2014-2016 epidemic in Sierra Leone showed a
88 seroreactivity of 8% among apparently healthy participants volunteering for an Ebola
89 vaccine trial, with no self-reported history of EVD [23]. Serosurveys in the DRC obtained
90 highly variable seroprevalence estimates depending on the region and the target group.
91 While the EBOV seroprevalence in Boende after the previous epidemic of 2014 was high
92 (28.1%) among healthy HCP never reporting an infection [24], the seroprevalence
93 estimate was much lower in another study conducted in the same area (7%) [22]. A
94 serosurvey conducted on blood samples collected from clinically suspected EVD cases
95 that were sent home after testing negative in two consecutive EBOV RT-PCR during the

96 tenth EBOV outbreak in DRC Ituri, Nord Kivu and Sud Kivu provinces, 2018-2020),
97 reported an EBOV antigen seroreactivity of 2.3% [25] (Table 1).
98 However, despite many studies assessing the GP-EBOV antigen seroreactivity in different
99 populations and different locations/countries, the interpretation of this seroprevalence
100 data is challenging given the variation of the assays employed and diversity of cutoff
101 algorithms used [8, 12, 18, 26-28]. Seroreactivity to a single EBOV antigen may not be
102 sufficient to demonstrate prior exposure to EBOV, especially in asymptotically infected
103 persons [29, 30]. Despite the broad range of EBOV seroprevalence rates in the EBOV
104 endemic areas, previous serological surveys may have overestimated seroprevalence
105 rates due to cross-reactivity against other infectious diseases (i.e. low specificity) [10, 28].
106 The use of more specific assays to determine the seroreactivity based on at least two
107 antigens may therefore provide a better understanding of the baseline seroprevalence
108 before a vaccine immunogenicity assessment [31, 32].
109 The study presented here, combines (1) the seroresults of baseline blood samples
110 collected among HCP and frontliners participating in the EBL2007 vaccine trial which
111 evaluates the safety and immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo
112 Ebola virus vaccine regimen (ClinicalTrials.gov identifier: NCT04186000) with (2) the
113 results from an ecological survey to determine information related to the current and past
114 residence and work locations of a cohort of HCP included in the EBL2007 vaccine trial
115 [33]. On the baseline blood samples collected, pre-existing antibodies against EBOV
116 among the participants were assessed using both FANG ELISA and Luminex assay.
117 While the first assay only targets IgG antibodies against the glycoprotein (GP) of EBOV,
118 the second assay also targets the nucleocapsid (NP) and the viral matrix protein 40
119 (VP40) which increases its specificity to 99% [34]. This manuscript reports the baseline

- 120 seroprevalence of Ebolavirus Zaire (EBOV) among HCP and frontliners participants in the
- 121 EBL2007 trial conducted in the health district of Boende in DRC.

122 **Materials and Methods**

123

124 **Origin of samples**

125

126 Baseline serum samples were collected before vaccination in an open-label, monocentric,
127 phase 2, randomized trial to evaluate the immunogenicity and safety of Ad26.ZEBOV and
128 MVA-BN-Filo in healthy HCP and frontliners in Boende Health District of DRC (EBL2007
129 trial, ClinicalTrials.Gov: NCT04186000) [33]. The trial site was located in the Boende
130 General Hospital of Tshuapa province at approximately 750 km north-west of the capital
131 city of Kinshasa in DRC. Blood samples were collected from healthy participants with no
132 reported history of EVD or previous EBOV vaccination. During the first visit of the
133 EBL2007 trial serum samples were collected for baseline determination of IgG GP-EBOV
134 by the means of FANG ELISA and Luminex assay. At one year after inclusion of
135 participants in the EBL2007 vaccine trial, a survey nested within the EBL2007 vaccine
136 trial collected information related to where HCPs and frontliners lived and worked in the
137 past, and their previous contacts with EVD cases.

138 **Operational definition**

139

140 The HCP term in the EBL2007 vaccine trial included medical doctors, nurses, midwives,
141 laboratory staff, pharmacy staff, hygienists, health facility cleaners, and nursing assistants
142 working in a hospital, Health Center, Health Post, or Health District office. Frontliners
143 encompassed community health workers, first aiders, and those working in the Health
144 District office and or the Provincial Division of Health. Direct contact was defined as any
145 HCP and frontliners who may have had direct interaction with patients infected with EVD
146 at a hospital or treatment center during an outbreak. Indirect contact was considered the

147 work of frontliners and other HCPs whose jobs did not bring them into direct interaction
148 with sick patients but could bring them in contact with contaminated material.

149 **Serological testing**

150
151 The study was performed according to the good clinical laboratory practice guidelines of
152 the Division of Acquired Immunodeficiency Syndrome and WHO [35, 36] to ensure high
153 quality, reliable, and reproducible data at Q Squared Solutions (San Juan Capistrano, CA,
154 US) Vaccine Testing Laboratory for FANG ELISA and Institut National de Recherche
155 Biomédicale (INRB) in DRC for the Luminex Assay.

156 **LUMINEX Assay technology**

157
158 The serology testing was performed with Luminex Magpix[®] technology (Luminex Corp.,
159 Austin, TX) as per the previously published protocol [17, 32]. Four recombinant
160 commercially available EBOV antigens were coated onto magnetic beads: two
161 glycoproteins, GP-EBOV-kis (Kissidougou/Makona 2014 strain) and GP-EBOV-m
162 (Mayinga 1976 strain); 1 nucleoprotein, NP-EBOV-m (Mayinga 1976 strain); and 1 40-
163 kDa viral protein (VP40-EBOV-m, Mayinga 1976 strain). The bead-coupled antigens were
164 mixed with the patient sample (1:1000 sample to dilution buffer), and the signal from the
165 response for anti-EBOV immunoglobulin G (anti-IgG) was read and stored on Bio-Plex
166 200 hardware (Bio-Rad, Marnes-la-Coquette, France). All results were reported as the
167 median fluorescence intensity (MFI). Based on the serological responses, a participant
168 was deemed to bear the pre-existing antibodies against EBOV antigens when the sample
169 was reactive above the cutoff for at least two different EBOV antigens.

170

171

172 **FANG ELISA**

173 The methods used to perform the FANG ELISA have been described in previous studies
174 [37]. Before the addition of test samples, 96-well microplates were coated with 100 μ L of
175 recombinant GP-EBOV-Kikwit (k) and incubated at 4°C in the absence of light. In addition
176 to this, a standard obtained from one or more serially diluted vaccinated donors had been
177 added. Incubation was performed by adding horseradish peroxidase conjugate from goat
178 anti-human IgG to each well. The substrate 3, 3', 5, 5'-tetramethylbenzidine was then
179 incorporated into each well. The addition of sulfuric acid solution stopped the enzymatic
180 reaction. The color change was then observed with a plate reader. The plate reader was
181 used to report the quality controls as well as the concentrations of the added samples.
182 The concentrations of these samples were based on the standard curve calculated using
183 a 4-parameter logistic curve (4PL) and are expressed as ELISA units/ml (EU/ml). Final
184 titers were determined based on a cutoff optical density (OD) value and were reported as
185 the reciprocal of the highest dilution with a positive OD value.

186
187 **Sample Size and Statistical Analysis**

188
189 The number of participants eligible for the EBL2007 trial with available aliquots (n=698) at
190 the inclusion visit predetermined the number of enrolled subjects in the serosurvey.
191 Subjects reacting to EBOV antigens (GP, NP, VP40) were summarized using proportions
192 with 95% confidence interval. Demographic and ecological data were compiled and
193 summarized using descriptive statistics for all participants enrolled in the EBL2007
194 vaccine trial using SPSS 28.0 IBM SPSS Statistics for Windows, version 28.0 and R 4.2.1
195 Statistical Software.

196 Both the FANG ELISA and Luminex assay do not have an established cutoff to distinguish
197 individuals with seroreactivity to an EBOV antigen. In the absence of a representative
198 control panel to estimate a cutoff, we calculated cutoff values by change point analysis
199 [38] using R [39]. In the supplementary information, we also provide seroprevalence
200 estimates based on cutoff values obtained from literature.

201 To further investigate if the signal of the antibody assay represents true past exposure to
202 EBOV, we tested if participants from the EBOV risk groups (based on age, sex, direct or
203 indirect contact with patients in general, working in a hospital or elsewhere, previous
204 contact with Ebola patients or experienced an outbreak at a location where you lived) were
205 significantly more likely to be antibody positive. We used a generalized linear model with
206 binomial link function. For each individual antigen, the participant's seropositivity status
207 was included as response variable and the participant characteristics as explanatory
208 variables. Only combinations of the Luminex GP-EBOV-m+VP40-EBOV were considered,
209 as the sample size of the positive group was too small for all other combinations. P-values
210 were considered significant below a value of 0.05.

211 **Ethics statements**

212 The National Ethics Committee of the DRC Ministry of Health approved the study protocol
213 of EBL2007 (approval reference n°121/CNES/BN/PMMF/2019). The ecological survey
214 nested in the EBL2007 Vaccine trial was approved by the National Ethics Committee of
215 the DRC Ministry Health under approval reference n°212/CNES/BN/PMMF/2020. For both
216 the EBL2007 trial and the ecological survey participants provided written informed
217 consent.

218

219 **Results**

220 **Participants characteristics**

221 A total of 720 HCPs and frontliners were screened for inclusion in the EBL2007 trial, of
222 which 699 (96.9%) agreed to participate in the baseline seroprevalence study. However,
223 one participant withdrew consent prior to blood collection. Thus, blood samples were
224 available for 698 (99.9%) participants with a mean age of 45 years (standard
225 deviation=12.0) and 534 (76.5%) were male (**Table 2**). Nearly two-thirds of the HCPs and
226 frontliners [492 (70.5%)] worked in a health facility in the Boende Health District and 410
227 (59.0%) were HCPs working in direct contact with patients. Forty-three (6.2%) of them
228 reported a direct contact with patients during a previous Ebola outbreak in Boende or
229 elsewhere. From a minority (3.5%) we are not sure if they ever had contact with infectious
230 patients during an ebola outbreak.

231
232 **Seroreactivity to EBOV proteins using FANG ELISA and or Luminex**
233
234 When considering antibody responses against EBOV antigens individually, we found that
235 8.4% (59/698; 95%CI 6.5 -10.6) of samples tested positive on the Luminex for GP-EBOV-
236 m, 9.4% (66/698;95%CI 7.5 -11.8) for GP- EBOV-kis, 9.4% (87/698;95%CI10.3-12.9) for
237 VP40-EBOV-m, and 1.3% (9/698;95%CI0.6-2.6) for NP-EBOV-m (Table 3). The
238 seroreactivity to at least two EBOV antigens using Luminex was encountered in 1.4%
239 (10/698;95%CI0.7-2.6) and 0.3% (2/698;95%CI0.0-1.0) of sera for VP40-EBOV-m + GP-
240 EBOV-m and VP40-EBOV-m + NP-EBOV-m respectively. No sera tested positive for NP-
241 EBOV-m+GP-EBOV-m.
242 GP-EBOV-m seroreactivity on the FANG ELISA was found in 7.1% (49/698; 95%CI6.5-
243 10.9) of participants' sera. Looking at participants whose GP-EBOV seroreactivity was
244 identified in both Luminex and FANG ELISA, 0.8% (6/694; 95%CI0.1-1.5) of the tested
245 samples were positive. We performed seroreactivity analyses using cutoffs determined in
246 the literature and found similar results as depicted in the Supplementary material.
247 A weak correlation between the FANG ELISA and Luminex was shown ($k=0.2$) (Figure 1).
248 In seeking which participant characteristics influenced seropositivity, we observed
249 significant differences in the seropositivity rate between HCPs and frontliners who
250 previously made direct contact with an Ebola patient or experienced an outbreak in their
251 hometown. When looking at the GP-EBOV-k antigen, HCPs and frontliners who previously
252 became into contact with Ebola were significantly less likely to be seropositive compared
253 to HCPs and frontliners who never experienced an Ebola outbreak (estimate=-1.22, std.
254 error = 0.52, $P=0.02$). When looking at the GP-EBOV-m, seropositivity status significantly
255 decreased with age (estimate = -0.02, est.error = 0.01, $P=0.04$).

256 **Discussion**

257

258 We report the baseline seroreactivity to EBOV-m antigens in apparently healthy HCPs
259 and frontliners enrolled in the EBL2007 vaccine trial.

260 Based on seroreactivity in two different assay formats (FANG ELISA and Luminex), only
261 a minority (0.8%) of HCPs and frontliners blood samples seroreacted to the GP-EBOV-m
262 surface antigen. Similarly, a minority of participants sera tested positive to at least two
263 antigens on the Luminex (0.3% for NP+VP40 EBOV-m and 1.4 for GP-EBOV-m+VP40-
264 EBOV-m). None of the participants sera tested positive to GP-EBOV-m+NP-EBOV-m.

265 Additionally, when we investigated whether seropositivity correlated with participants' prior
266 exposure to EBOV-m, we did not observe a relevant positive correlation. This suggests
267 that the majority of seropositive participants implied on the basis of the single antigen
268 analysis are in fact false positives.

269 Overall, these results suggest that the baseline seroprevalence against EBOV-m in HCPs
270 and frontliners in Boende is very low. Our seroprevalence estimates are much lower
271 compared to previous serosurveys conducted after the EVD outbreak of 2014 in HCP of
272 Boende Health District (22.5% and 28%) (GP-EBOV-m seroreactivity using ELISA) [12,
273 27]. Our estimates are also lower than the one previously reported in Boende Health
274 District among the general population (7%) (GP-EBOV-m seroreactivity using ELISA) a
275 year after the 2014 Ebola epidemic [22]. The seroprevalence based on one EBOV-m
276 antigen (GP-EBOV-m) found in this study using either ELISA or Luminex is lower than
277 other peviously reported in the Watsa Pygmy population of DRC in 2002 (18.7%) (GP-
278 EBOV-m seroreactivity using ELISA) and the Sankuru rural population in 2007 (11%) (GP-
279 EBOV-m seroreactivity using ELISA) [8, 21].

280 By employing this approach, our seroprevalence estimates became comparable to those
281 of previous serological surveys conducted in Kikwit (2.2%) (GP-EBOV-m seroreactivity by
282 ELISA) and Kinshasa (2%) (GP-EBOV-m seroreactivity by luciferase immunoprecipitation
283 system + neutralization) [18, 40].

284 It is worth noting that LUMINEX built on an approach of simultaneously targeting multiple
285 EBOV antigens, demonstrated a specificity (99.1%) and a sensitivity (95.7%) similar to
286 higher than, respectively, the specificity (100%) and sensitivity (92.5%) of the commercial
287 ELISA in a study [32]. The FANG ELISA was developed and validated to quantify Filovirus
288 anti-EBOV-GP immunoglobulin G (IgG) binding antibodies in human and non-human
289 primate serum sample to enable bridging of immunogenicity data between humans and
290 animal models in vaccine trials [37].

291 The higher seroprevalences found in other serosurveys conducted in Boende or
292 elsewhere in the DRC may be explained by the fact that different assays were used in the
293 different studies, other cutoff algorithms were used, and the definition of reactivity
294 discrimination (one or two EBOV antigens) may have decreased the specificity of these
295 assays. This could have led to overestimation of EBOV antigen seropositivity. On the other
296 hand, it cannot be ruled out that more people were indeed infected during the 2014
297 outbreak in Boende and that antibody titers waned over time or at least dropped below
298 the detection threshold, explaining the low seroprevalence that we observed. Likewise,
299 this low prevalence may reflect a rare incidence of asymptomatic EBOV infection among
300 HCP and frontliner population from the Boende Health District. The previous scenario may
301 reflect a susceptibility to future outbreaks of EBOV. Yet, negative antibody titers do not
302 rule out other types of immunity, such as T-cell immunity [41].

303 FANG ELISA or Luminex are assays that can only detect binding antibodies and are
304 unable to differentiate them from neutralizing antibodies [37]. The latter are typically
305 detected using neutralization assays, which are still considered the gold standard for
306 serological testing [42, 43]. However, such testing involves infectious cells, are labour
307 intensive and time consuming [44]. For viruses such as EBOV, all experiments should be
308 performed under a biosafety laboratory (BSL)-4 conditions, which are limited in availability
309 and expensive to operate [45]. Thus, it is beneficial to use alternative neutralization assays
310 that do not require viruses or live cells, and that can be performed in BSL-2 laboratories
311 to assess neutralizing antibody capacity [44, 46]. These alternative assays should
312 conclude if a person with high binding antibodies against EBOV (based on FANG ELISA
313 or Luminex) was indeed infected with the virus (although some level of cross-reactivity
314 can never be ruled out) [29]. The challenge of comparing different serosurveys that have
315 assessed the EBOV seroprevalence makes the implementation of international
316 standardization of units for EBOV antibody detection and quantification of paramount
317 importance [47].

318 The poor linear relationship between the two assays used (FANG ELISA and Luminex) in
319 this serosurvey confirms that both assays likely contain many false positive results, when
320 using single antigens. Hence, the reported seropositivity could be an effect of other
321 filoviruses or infectious microbes, which may cause cross-reactions [48].

322 A limitation of our study is the lack of positive and negative control samples to determine
323 the positive cutoff. However, in the absence of a standard serological assay for EBOV
324 seroreactivity, Luminex can still be employed in serosurveys due to its ability to detect
325 seroreactivity to combinations of different EBOV antigens [32].

326 The strength of this survey resides in the use of high cutoffs to determine the EBOV
327 seropositivity that aligns with recommendations in EBOV serosurveys generally applied
328 to Congolese cohorts [18, 28, 49]. Thus, the combination of FANG ELISA and Luminex
329 results can be considered a starting point, showing how previous serological surveys may
330 have overestimated the seroprevalence of EBOV in a non-exempt area. Like the recent
331 index case of the fourteenth outbreak in DRC (Mbandaka, 2022), whose symptoms began
332 three weeks after returning from Boende with no notion of contact with an Ebola survivor
333 [5]. The next step could be the use of a neutralization assay for assessment of neutralizing
334 antibodies among this population of HCP and frontliners participants in the EBL2007 trial
335 to further document whether or not this population of HCP is naive to EBOV exposure.
336 The low baseline seroreactivity to EBOV antigens observed in HCP and frontliner
337 population of Boende suggests that the majority of this population never came into contact
338 with the virus, despite the fact the many HCP and frontliners worked during previous EBV
339 outbreak in 2014. In the event of a future epidemic, mathematical models suggested that
340 the vaccination rate of HCP in an infected area should be at least (30%) to prevent a major
341 epidemic [50]. Therefore it is clear that HCP in endemic regions should be primary targets
342 for vaccination in the frame of the Ebola epidemic preparedness plan in DRC [50].

343 **Conclusion**

344
345 In contrast to previous studies that observed high seroreactivity against EBOV-m in
346 Boende, our results show that the baseline seroprevalence of HCP and frontliners that
347 reported no previous EBOV infections is low. This suggests that asymptomatic infections
348 are unlikely to occur or that antibodies rapidly wane after infection (or at least drop below
349 the cutoff of detection). Irrespective of the cause, it means that the majority of HCPs in
350 the area are likely susceptible to EVD despite the history of outbreaks in and the area of
351 Boende. Given the high variance between seroprevalence estimates by different studies
352 in the same region, we highlight the need for more uniform antibody assays. Neutralizing
353 antibody quantification methods, which are inexpensive in terms of resources, are likely
354 to be crucial for improving EVD surveillance in this region, given the high background of
355 concomitant parasitic disease burden that can be expected to be found in the serum of
356 this population. Low resources affordable approaches to quantifying neutralizing
357 antibodies are likely to be crucial in enhancing surveillance of EVD disease in this region.

358 **Acknowledgments**

359
360 The authors gratefully acknowledge the hard work and dedication of the local trial staff.
361 The supportive role of ACE Research, DFNet Research, Q² Solutions and Institut National
362 de Recherche Biomédicale (INRB) and all partners within the EBOVAC3 Consortium is
363 highly appreciated.

364 **Financial support**

365
366 This work was supported by the EBOVAC3. This project has received funding from the
367 Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 800176
368 (IMI-EU). This Joint Undertaking receives support from the European Union's Horizon
369 2020 research and innovation pro-gramme, European Federation of Pharmaceutical
370 Industries and Associations (EFPIA) and the Coalition for Epidemic Preparedness
371 Innovations (CEPI). All vaccines were provided by Janssen Vaccines & Prevention B.V.

372 **Potential conflicts of interest**

373
374 The authors declare that they have no known competing financial interests or personal
375 relationships that could have appeared to influence the work reported in this paper.

376

377 **References**

- 378
- 379 1. Team WIS: **Ebola haemorrhagic fever in Sudan, 1976.** *Bulletin of the World Health Organization*
- 380 1978, **56(2):247-270.**
- 381 2. **Ebola haemorrhagic fever in Zaire, 1976.** *Bull World Health Organ* 1978, **56(2):271-293.**
- 382 3. **Epidémie de la Maladie à Virus Ebola, Province de l'Equateur, République Démocratique du**
- 383 **Congo (24/04/2022)** [<https://reliefweb.int/organization/who>]
- 384 4. **Le Gouvernement déclare la fin de l'épidémie de la maladie à virus Ebola dans la Zone de santé**
- 385 **de Boende | Province de l'Equateur, Nord-ouest de la RDC**
- 386 [<https://reliefweb.int/organization/who>]
- 387 5. Makoni M: **Ebola outbreak in DR Congo.** *The Lancet* 2022, **399(10337):1766.**
- 388 6. Tyukavina A, Hansen MC, Potapov P, Parker D, Okpa C, Stehman SV, Kommareddy I, Turubanova
- 389 S: **Congo Basin forest loss dominated by increasing smallholder clearing.** *Science advances*
- 390 2018, **4(11):eaat2993.**
- 391 7. Gryseels S, Mbala-Kingebeni P, Akonda I, Angoyo R, Ayouba A, Baelo P, Mukadi DB, Bugentho E,
- 392 Bushmaker T, Butel C *et al*: **Role of Wildlife in Emergence of Ebola Virus in Kaigbono (Likati),**
- 393 **Democratic Republic of the Congo, 2017.** *Emerg Infect Dis* 2020, **26(9):2205-2209.**
- 394 8. Mulangu S, Borchert M, Paweska J, Tshomba A, Afounde A, Kulidri A, Swanepoel R, Muyembe-
- 395 Tamfum J-J, Van der Stuyft P: **High prevalence of IgG antibodies to Ebola virus in the Efé pygmy**
- 396 **population in the Watsa region, Democratic Republic of the Congo.** *BMC infectious diseases*
- 397 2016, **16(1):1-6.**
- 398 9. Diallo B, Sissoko D, Loman NJ, Bah HA, Bah H, Worrell MC, Conde LS, Sacko R, Mesfin S, Loua A:
- 399 **Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in**
- 400 **seminal fluid for more than 500 days.** *Clinical infectious diseases* 2016, **63(10):1353-1356.**
- 401 10. de La Vega M-A, Stein D, Kobinger GP: **Ebolavirus evolution: past and present.** *PLoS pathogens*
- 402 2015, **11(11):e1005221.**
- 403 11. Dhama K, Malik YS, Malik SVS, Singh RK: **Ebola from emergence to epidemic: the virus and the**
- 404 **disease, global preparedness and perspectives.** *The Journal of Infection in Developing Countries*
- 405 2015, **9(05):441-455.**
- 406 12. Doshi RH, Hoff NA, Bratcher A, Mukadi P, Gadoth A, Nicholson BP, Williams R, Mukadi D,
- 407 Mossoko M, Wasiswa J: **Risk Factors for Ebola Exposure in Health Care Workers in Boende,**
- 408 **Tshuapa Province, Democratic Republic of the Congo.** *The Journal of Infectious Diseases* 2020.
- 409 13. Maganga GD, Kapetshi J, Berthet N, Kebela Ilunga B, Kabange F, Mbala Kingebeni P, Mondonge
- 410 V, Muyembe J-JT, Bertherat E, Briand S: **Ebola virus disease in the Democratic Republic of**
- 411 **Congo.** *New England Journal of Medicine* 2014, **371(22):2083-2091.**
- 412 14. **History of Ebola Virus Disease (EVD) Outbreaks**
- 413 [<https://www.cdc.gov/vhf/ebola/history/chronology.html>]
- 414 15. Baller A, Padoveze MC, Mirindi P, Hazim CE, Lotemo J, Pfaffmann J, Ndiaye A, Carter S, Chabrat
- 415 M-AD, Mangala S: **Ebola virus disease nosocomial infections in the Democratic Republic of the**
- 416 **Congo: a descriptive study of cases during the 2018–2020 outbreak.** *International Journal of*
- 417 *Infectious Diseases* 2022, **115:126-133.**
- 418 16. Muyembe-Tamfum J, Kipasa M, Kiyungu C, Colebunders R: **Ebola outbreak in Kikwit, Democratic**
- 419 **Republic of the Congo: discovery and control measures.** *The Journal of infectious diseases* 1999,
- 420 **179(Supplement_1):S259-S262.**
- 421 17. Diallo MSK, Rabilloud M, Ayouba A, Touré A, Thaurignac G, Keita AK, Butel C, Kpamou C, Barry
- 422 TA, Sall MD: **Prevalence of infection among asymptomatic and paucisymptomatic contact**

- 423 **persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study.**
424 *The Lancet Infectious Diseases* 2019, **19**(3):308-316.
- 425 18. Steffen I, Lu K, Yamamoto LK, Hoff NA, Mulembakani P, Wemakoy EO, Muyembe-Tamfum JJ,
426 Ndembi N, Brennan CA, Hackett J, Jr. *et al*: **Serologic Prevalence of Ebola Virus in Equatorial**
427 **Africa.** *Emerg Infect Dis* 2019, **25**(5):911-918.
- 428 19. Shaffer KC, Hui S, Bratcher A, King LB, Mutombe R, Kavira N, Kompany JP, Tambu M, Musene K,
429 Mukadi P: **Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health**
430 **Region, Democratic Republic of the Congo.** *PLOS Neglected Tropical Diseases* 2022,
431 **16**(3):e0010167.
- 432 20. Moyen N, Thirion L, Emmerich P, Dzia-Lepfoundzou A, Richet H, Boehmann Y, Dimi Y, Gallian P,
433 Gould EA, Günther S: **Risk factors associated with Ebola and Marburg viruses seroprevalence in**
434 **blood donors in the Republic of Congo.** *PLoS neglected tropical diseases* 2015, **9**(6):e0003833.
- 435 21. Mulangu S, Alfonso VH, Hoff NA, Doshi RH, Mulembakani P, Kisalu NK, Okitolonda-Wemakoy E,
436 Kebela BI, Marcus H, Shiloach J: **Serologic evidence of ebolavirus infection in a population with**
437 **no history of outbreaks in the Democratic Republic of the Congo.** *The Journal of Infectious*
438 *Diseases* 2018, **217**(4):529-537.
- 439 22. Bratcher A, Hoff NA, Doshi RH, Gadoth A, Halbrook M, Mukadi P, Musene K, Ilunga-Kebela B,
440 Spencer D, Bramble MS *et al*: **Zoonotic risk factors associated with seroprevalence of Ebola**
441 **virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic**
442 **of Congo.** *PLoS Negl Trop Dis* 2021, **15**(8):e0009566.
- 443 23. Manno D, Ayieko P, Ishola D, Afolabi MO, Rogers B, Baiden F, Serry-Bangura A, Bah OM, Köhn B,
444 Swaray I *et al*: **Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected**
445 **by Ebola, Sierra Leone.** *Emerg Infect Dis* 2022, **28**(3):734-738.
- 446 24. Hoff NA, Mukadi P, Doshi RH, Bramble MS, Lu K, Gadoth A, Sinai C, Spencer D, Nicholson BP,
447 Williams R *et al*: **Serologic Markers for Ebolavirus Among Healthcare Workers in the**
448 **Democratic Republic of the Congo.** *J Infect Dis* 2019, **219**(4):517-525.
- 449 25. Nkuba-Ndaye A, Mukadi-Bamuleka D, Bulabula-Penge J, Thaurignac G, Edidi-Atani F, Mambu-
450 Mbika F, Danga-Yema B, Matondo-Kuamfumu M, Kinganda-Lusamaki E, Bisento N: **Added value**
451 **of an anti-Ebola serology for the management of clinically suspected Ebola virus disease**
452 **patients discharged as negative in an epidemic context.** *The Journal of Infectious Diseases* 2022.
- 453 26. Mbala P, Baguelin M, Ngay I, Rosello A, Mulembakani P, Demiris N, Edmunds WJ, Muyembe J-J:
454 **Evaluating the frequency of asymptomatic Ebola virus infection.** *Philosophical Transactions of*
455 *the Royal Society B: Biological Sciences* 2017, **372**(1721):20160303.
- 456 27. Hoff NA, Mukadi P, Doshi RH, Bramble MS, Lu K, Gadoth A, Sinai C, Spencer DA, Nicholson BP,
457 Williams R: **Serologic markers for ebolavirus among healthcare workers in the Democratic**
458 **Republic of the Congo.** *The Journal of infectious diseases* 2019, **219**(4):517-525.
- 459 28. Bratcher A, Hoff NA, Doshi RH, Gadoth A, Halbrook M, Mukadi P, Musene K, Ilunga-Kebela B,
460 Spencer DA, Bramble MS: **Zoonotic risk factors associated with seroprevalence of Ebola virus**
461 **GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of**
462 **Congo.** *PLoS Neglected Tropical Diseases* 2021, **15**(8):e0009566.
- 463 29. Richardson ET, Kelly JD, Barrie MB, Mesman AW, Karku S, Quiwa K, Marsh RH, Koedoyoma S,
464 Daboh F, Barron KP: **Minimally symptomatic infection in an Ebola ‘hotspot’: a cross-sectional**
465 **serosurvey.** *PLoS neglected tropical diseases* 2016, **10**(11):e0005087.
- 466 30. Becquart P, Mahlaköiv T, Nkoghe D, Leroy EM: **Identification of continuous human B-cell**
467 **epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus.** *PLoS one* 2014,
468 **9**(6):e96360.
- 469 31. Rudge Jr TL, Sankovich KA, Niemuth NA, Anderson MS, Badorrek CS, Skomrock ND, Cirimotich
470 CM, Sabourin CL: **Development, qualification, and validation of the Filovirus Animal Nonclinical**

- 471 **Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay**
472 **for human serum samples.** *PLoS one* 2019, **14**(4):e0215457.
- 473 32. Ayouba A, Touré A, Butel C, Keita AK, Binetruy F, Sow MS, Foulongne V, Delaporte E, Peeters M:
474 **Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for**
475 **Detection of Antibodies to Zaire Ebola Virus.** *J Clin Microbiol* 2017, **55**(1):165-176.
- 476 33. Larivière Y, Zola T, Stoppie E, Maketa V, Matangila J, Mitashi P, De Bie J, Muhindo-Mavoko H, Van
477 Damme P: **Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of**
478 **a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine**
479 **regimen against Ebola in the Democratic Republic of the Congo: the study protocol.** *BMJ open*
480 2021, **11**(9):e046835.
- 481 34. Ayouba A, Touré A, Butel C, Keita AK, Binetruy F, Sow MS, Foulongne V, Delaporte E, Peeters M:
482 **Development of a sensitive and specific serological assay based on Luminex technology for**
483 **detection of antibodies to Zaire Ebola virus.** *Journal of clinical microbiology* 2017, **55**(1):165-
484 176.
- 485 35. Health Nlo: **Guidelines for good clinical laboratory practice standards.** *Bethesda, MD, USA:*
486 *National Institutes of Health* 2019.
- 487 36. Stevens W: **Good clinical laboratory practice (GCLP): the need for a hybrid of good laboratory**
488 **practice and good clinical practice guidelines/standards for medical testing laboratories**
489 **conducting clinical trials in developing countries.** *Quality Assurance* 2003, **10**(2):83-89.
- 490 37. Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, Pettitt J, Stavale EJ, Fallah M,
491 Olinger GG: **Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay**
492 **requires fewer study participants to power a study than the Alpha Diagnostic International**
493 **assay.** *Journal of virological methods* 2018, **255**:84-90.
- 494 38. Lardeux F, Torrico G, Aliaga C: **Calculation of the ELISA's cut-off based on the change-point**
495 **analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence**
496 **of controls.** *Mem Inst Oswaldo Cruz* 2016, **111**(8):501-504.
- 497 39. Killick R, Eckley I: **changepoint: An R package for changepoint analysis.** *Journal of statistical*
498 *software* 2014, **58**(3):1-19.
- 499 40. Busico KM, Marshall KL, Ksiazek TG, Roels TH, Fleerackers Y, Feldmann H, Khan AS, Peters C:
500 **Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic**
501 **Republic of the Congo, 1995.** *The Journal of Infectious Diseases* 1999, **179**(Supplement_1):S102-
502 S107.
- 503 41. Thom R, Tipton T, Strecker T, Hall Y, Akoi Bore J, Maes P, Raymond Koundouno F, Fehling SK,
504 Krähling V, Steeds K *et al*: **Longitudinal antibody and T cell responses in Ebola virus disease**
505 **survivors and contacts: an observational cohort study.** *Lancet Infect Dis* 2021, **21**(4):507-516.
- 506 42. Rimoin AW, Lu K, Bramble MS, Steffen I, Doshi RH, Hoff NA, Mukadi P, Nicholson BP, Alfonso VH,
507 Olinger G: **Ebola virus neutralizing antibodies detectable in survivors of the Yambuku, Zaire**
508 **outbreak 40 years after infection.** *The Journal of infectious diseases* 2018, **217**(2):223-231.
- 509 43. Deshpande GR, Sapkal GN, Tilekar BN, Yadav PD, Gurav Y, Gaikwad S, Kaushal H, Deshpande KS,
510 Kaduskar O, Sarkale P: **Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.**
511 *The Indian journal of medical research* 2020, **152**(1-2):82.
- 512 44. Mariën J, Michiels J, Heyndrickx L, Nkuba-Ndaye A, Ceulemans A, Bartholomeeusen K, Madinga J,
513 Mbala-Kingebeni P, Vanlerberghe V, Ahuka-Mundeke S: **Evaluation of a surrogate virus**
514 **neutralization test for high-throughput serosurveillance of SARS-CoV-2.** *Journal of Virological*
515 *Methods* 2021, **297**:114228.
- 516 45. Burnett LC, Lunn G, Coico R: **Biosafety: guidelines for working with pathogenic and infectious**
517 **microorganisms.** *Current protocols in microbiology* 2009, **13**(1):1A. 1.1-1A. 1.14.

- 518 46. Cao Z, Jin H, Wong G, Zhang Y, Jiao C, Feng N, Wu F, Xu S, Chi H, Zhao Y: **The Application of a**
519 **Safe Neutralization Assay for Ebola Virus Using Lentivirus-Based Pseudotyped Virus.** *Virologica*
520 *Sinica* 2021, **36**(6):1648-1651.
- 521 47. **WHO International Standard 1st International Standard for Ebola virus (EBOV) antibodies -**
522 **Sierra Leone Convalescent Plasma Pool NIBSC code: 15/262 Instructions for use**
523 [<https://www.nibsc.org/documents/ifu/15-262.pdf>]
- 524 48. MacNeil A, Reed Z, Rollin PE: **Serologic cross-reactivity of human IgM and IgG antibodies to five**
525 **species of Ebola virus.** *PLoS neglected tropical diseases* 2011, **5**(6):e1175.
- 526 49. Kuhn J: **Filoviruses: a compendium of 40 years of epidemiological, clinical, and laboratory**
527 **studies.** 2008.
- 528 50. Potluri R, Kumar A, Maheshwari V, Smith C, Oriol Mathieu V, Luhn K, Callendret B, Bhandari H:
529 **Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis.**
530 *Plos one* 2020, **15**(4):e0230406.

531 **Table 1.** EBOV seroprevalence estimates using different Assays in DRC

Area of DRC	Year	*EBOV Seroprevalence (%)	Assay	CI	Population	Sample size (N)	Studies
Kikwit	1995	2.2	ELISA	0.3 – 4.0	Forest and City Workers	414	Busico et al. <i>Journal of Infectious Diseases</i> 1999, 79: S102-S107.
Watsa	2002	18.7	ELISA	14.4 – 23.5	General population (pygmy)	300	Mulangu et al. <i>BMC infectious diseases</i> 2016, 16.1: 1-6
Sankuru	2007	11.0	ELISA	9.9 – 12.7	General population	3415	Mulangu et al. <i>The Journal of Infectious Diseases</i> 2018, 217.4: 529-537
Kinshasa	2011 – 2012	2.0	Luciferase immunoprecipitation system + neutralization	0.7 – 5.1	Blood donors	752	Imke et al., <i>Emerging Infectious Diseases</i> . 25 (5) 2019
Boende	2015	22.5	ELISA	19.2 – 25.9	Healthcare workers	611	Doshi et al. <i>The Journal of Infectious Diseases</i> (2020).
Boende	2015	28.1	ELISA, Luciferase immunoprecipitation system + neutralization	24.4 – 31.4	Healthcare workers	565	Hoff et al. <i>The Journal of infectious diseases</i> , 2019, 219.4: 517-525
Boende	2015 – 2017	7.0	ELISA	5.0 – 8.8	General population	687	Bratcher et al. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15.8: e0009566.
Beni, Butembo, Katwa, and Mabalako	2018-2020	2.3	Luminex assay	1.1–4.0	Suspected cases of the tenth DRC epidemic of Ebola	600	Nkuba-Ndaye et al. <i>J Infect Dis.</i> 2022 ;226(2):352-356

532 *Seroprevalence based on the GP-EBOV antigen seroreactivity


533 **Table 2.** Participants characteristics

Characteristic	N=698	% Max	Mean (SD)	Min	Max
Age (year)			45.0 (12.0)	19	75
Sex					
Female	164	23.5			
Male	534	76.5			
Profession					
Community Health Worker	236	33.8			
Nurse	181	25.9			
First Aid Worker	177	25.4			
Hygienist	37	5.3			
Midwife	30	4.3			
Medical Doctor	13	1.9			
Health Facility Cleaner	10	1.4			
Care Giver	7	1.0			
Other	3	0.4			
Laboratory Technician	2	0.3			
Pharmacist Assistant	2	0.3			
Place of work in Boende					
Health Facility (Hopital, Centre de Santé, Poste de Santé)	492	70.5			
Health District Office (Bureau central Zone de Santé)	8	1.1			
Croix-Rouge Boende Inspection	177	25.4			
Provinciale de la Santé	1	0.1			
Aire de Santé	10	1.4			
Division Provinciale de la Santé	9	1.3			
Tshuapa Programme Elargi de Vaccination Boende	1	0.1			


535 **Table 3:** Seroprevalence for different (combinations of) antibodies against Ebola virus antigens as measured by the Luminex
 536 or FANG ELISA in Health care providers from Boende, DR Congo.

	Antigen	*Cutoff	Positives n (N)	Seroprevalence % (95% conf. Int.)	Age /year p-value	M vs F p-value	Direct Contact with patients: Direct vs indirect (p-value)	Working Hospital vs elsewhere (p-value)	Experienced Ebola outbreak/patients vs others p-value
FANG ELISA	GP-EBOV-k	526 EU/ml	59 (694)	8.5 (6.5, 10.9)	0.89	0.44	0.52	0.93	0.94
Luminex	GP-EBOV-m	669 MFI/100 beads	60 (698)	8.6 (6.5,10.7)	0.03	0.93	0.05	0.63	0.09
	GP-EBOV-kis	670 MFI/100 beads	66 (698)	9.4 (7.5,11.8)	0.05	0.99	0.05	0.52	0.005
	VP40-EBOV- m	441 MFI/100 beads	87 (698)	12.4 (10.3,14.9)	0.11	0.07	0.31	0.74	0.46
	NP-EBOV-m	602 MFI/100 beads	9 (698)	1.3 (0.6,2.6)	0.41	0.40	0.13	0.26	0.07
	GP-EBOV- m+NP- EBOV-m	C1	0 (698)	0					
	GP-EBOV- m+VP40- EBOV-m	C2	10 (698)	1.4 (0.7,2.6)	0.75	0.02	0.39	0.68	0.47
Luminex and FANG ELISA	GP-EBOV-m + GP-EBOV-k	C3	2 (698)	0.3 (0.0,1.0)					
		C4	6 (694)	0.8 (0.1,1.5)					

537 C1= 669MFI/100 beads for GP-EBOV-m and 602 MFI/100 beads for NP-EBOV-m
 538 C2= 669MFI/100 beads for GP-EBOV-m and 441 MFI/100beads fo VP40-EBOV-m
 539 C3= 602 MFI/100 beads for NP-EBOV-m and 441 MFI/100 beads for VP40-EBOV-m
 540 C4= 669 MFI/100 beads for GP-EBOV-m using Luminex and 526 EU/mL for GP-EBOV-k using FANG ELISA



541
542 **Figure 1** Pearson Correlation between FANG ELISA and Luminex
543 Seroreactivity against the glycoprotein (GP) of Ebola virus in health care providers from
544 Boende. The X axis reports the log values of the antibody titers (IgG) as measured by
545 Luminex in MFI/100 beads, while the Y axis represents antibody titers as measured by
546 FANG ELISA in EU/ml. The vertical dashed line in red represents the cutoff of the
547 changepoint analysis and the dashed horizontal line in green represents the cutoff
548 obtained from previous studies.



1
2 **Figure 1** Pearson Correlation between FANG ELISA and Luminex
3 Seroreactivity against the glycoprotein (GP) of Ebola virus in health care providers from
4 Boende. The X-axis reports the log values of the antibody titers (IgG) as measured by
5 Luminex in MFI/100 beads, while the Y-axis represents antibody titers as measured by
6 FANG ELISA in EU/ml. The vertical dashed line in red represents the cutoff of the
7 changepoint analysis and the dashed horizontal line in green represents the cutoff
8 obtained from previous studies.
9